Lantheus (NASDAQ:LNTH) Stock Rating Lowered by Brookline Capital Markets

Lantheus (NASDAQ:LNTH) was downgraded by equities researchers at Brookline Capital Markets from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

A number of other equities analysts also recently issued reports on the stock. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Finally, B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research report on Wednesday. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $109.71.

Lantheus Stock Down 2.6%

Lantheus stock opened at $100.00 on Tuesday. The stock has a market cap of $6.51 billion, a PE ratio of 24.10 and a beta of -0.06. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. Lantheus has a one year low of $47.25 and a one year high of $111.86. The stock has a fifty day moving average of $103.93 and a 200 day moving average of $86.41.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period last year, the firm posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts predict that Lantheus will post 4.5 EPS for the current year.

Institutional Investors Weigh In On Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versor Investments LP bought a new stake in shares of Lantheus during the 4th quarter valued at $519,000. M&T Bank Corp bought a new position in Lantheus in the 4th quarter worth $539,000. Epoch Investment Partners Inc. boosted its holdings in Lantheus by 59.4% in the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock worth $49,284,000 after buying an additional 242,222 shares during the period. Bleakley Financial Group LLC purchased a new stake in Lantheus in the 4th quarter worth $771,000. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its stake in Lantheus by 686.1% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after buying an additional 522,678 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.